32 Long Term Results of 120 Cases of Vestibular Schwannoma Treated with Cyberknifetm Robotic Stereotactic Radiosurgery at the Ottawa Hospital Cancer Centre

Gaviolli, Eduardo; Zheng, Jack; Sinclair, John; Szántó, J.; Alkherayf, Fahad; Malone, Julia; Nair, Vimoj; Gratton, Julie; Malone, Shawn

doi:10.1016/s0167-8140(19)33318-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 99 duplicates were removed, 123 articles were submitted an analysis of the title and abstract, and 77 were excluded. The 46 remaining articles had their full text read, and 33 were excluded due to the following reasons: the hearing classification system specified in the eligibility criteria was not used or it was used inadequately (for example: considering GR grade III or AAO-HNS class C as serviceable hearing); [15][16][17][18][19] inadequate study design; [20][21][22][23] incomplete study; [24][25][26][27][28][29][30][31][32][33][34] use of another radiation source; 35,36 same population from others studies; [37][38][39][40][41] and inadequate data report [42][43][44][45][46][47] (the corresponding authors of these studies were contacted to request additional information, but there was no response). Then, a total of 13 studies [48][49][50][51][52][53][54][55][56][57][58]…”

Section: Study Selectionmentioning

confidence: 99%

Hearing Function after CyberKnife for Vestibular Schwannoma: A Systematic Review

Tavares,

Bahmad Jr

2024

Int Arch Otorhinolaryngol

View full text Add to dashboard Cite

Introduction CyberKnife (CK) radiosurgery is a treatment strategy for vestibular schwannoma (VS). Objectives To evaluate hearing preservation (HP) after CK for VS. Data Synthesis The study was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, and it was registered at the International Prospective Register of Systematic Reviews (PROSPERO, under number CRD42021250300). The inclusion criteria were based on the population, intervention, comparison, outcome, timing and study design (PICOTS) strategy: population – patients with VS; intervention – CK; Comparison – none; Outcome – serviceable HP defined by Gardner and Robertson as grades I or II, or by the American Academy of Otolaryngology and Head and Neck Surgery as classes A or B; timing – mean follow-up longer than 1 year; and study design – retrospective or prospective studies. The exclusion criteria were: studies not published in English; studies published before January 2000 and after October 2021; and studies only including patients with neurofibromatosis type 2 or submitted to a previous treatment. The PubMed/MEDLINE, EMBASE, Web of Science, Cochrane Library, LILACS, and IBECS databases were used and last searched on October 27th, 2021. Statistical heterogeneity was assessed using I 2 statistics. The appraisal checklist was used to assess the risk of bias in the included studies. A total of 222 studies were analyzed, and 13 were included in the synthesis, which represents 493 participants with serviceable hearing before intervention. The mean HP rate after CK using a random effects model was of 68% (95% confidence interval [95%CI]: 59–76%) at a mean follow-up of 42.96 months. Conclusion The longer follow-up period was associated with a lower HP rate after CK radiosurgery for VS in the qualitative synthesis.

show abstract